Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164


TP53 and let-7a micro-RNA regulate K-Ras activity in HCT116 colorectal cancer cells.

Luu C, Heinrich EL, Duldulao M, Arrington AK, Fakih M, Garcia-Aguilar J, Kim J.

PLoS One. 2013 Aug 1;8(8):e70604. doi: 10.1371/journal.pone.0070604. Print 2013.


High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease.

Ruzzo A, Graziano F, Vincenzi B, Canestrari E, Perrone G, Galluccio N, Catalano V, Loupakis F, Rabitti C, Santini D, Tonini G, Fiorentini G, Rossi D, Falcone A, Magnani M.

Oncologist. 2012;17(6):823-9. doi: 10.1634/theoncologist.2012-0081. Epub 2012 May 14.


Overexpressed let-7a inhibits glioma cell malignancy by directly targeting K-ras, independently of PTEN.

Wang XR, Luo H, Li HL, Cao L, Wang XF, Yan W, Wang YY, Zhang JX, Jiang T, Kang CS, Liu N, You YP; Chinese Glioma Cooperative Group (CGCG).

Neuro Oncol. 2013 Nov;15(11):1491-501. doi: 10.1093/neuonc/not107. Epub 2013 Oct 3.


MicroRNA let-7a inhibits the proliferation and invasion of nonsmall cell lung cancer cell line 95D by regulating K-Ras and HMGA2 gene expression.

Wang YY, Ren T, Cai YY, He XY.

Cancer Biother Radiopharm. 2013 Mar;28(2):131-7. doi: 10.1089/cbr.2012.1307. Epub 2012 Nov 7.


Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma.

Duldulao MP, Lee W, Nelson RA, Li W, Chen Z, Kim J, Garcia-Aguilar J.

Ann Surg Oncol. 2013 Jul;20(7):2166-71. doi: 10.1245/s10434-013-2910-0. Epub 2013 Mar 2.


Targeted knock-in of the polymorphism rs61764370 does not affect KRAS expression but reduces let-7 levels.

Crowley EH, Arena S, Lamba S, Di Nicolantonio F, Bardelli A.

Hum Mutat. 2014 Feb;35(2):208-14. doi: 10.1002/humu.22487. Epub 2013 Dec 27.


MicroRNA-224 is associated with colorectal cancer progression and response to 5-fluorouracil-based chemotherapy by KRAS-dependent and -independent mechanisms.

Amankwatia EB, Chakravarty P, Carey FA, Weidlich S, Steele RJ, Munro AJ, Wolf CR, Smith G.

Br J Cancer. 2015 Apr 28;112(9):1480-90. doi: 10.1038/bjc.2015.125.


Let-7a regulates mammosphere formation capacity through Ras/NF-κB and Ras/MAPK/ERK pathway in breast cancer stem cells.

Xu C, Sun X, Qin S, Wang H, Zheng Z, Xu S, Luo G, Liu P, Liu J, Du N, Zhang Y, Liu D, Ren H.

Cell Cycle. 2015;14(11):1686-97. doi: 10.1080/15384101.2015.1030547.


Androgen receptor decreases CMYC and KRAS expression by upregulating let-7a expression in ER-, PR-, AR+ breast cancer.

Lyu S, Yu Q, Ying G, Wang S, Wang Y, Zhang J, Niu Y.

Int J Oncol. 2014 Jan;44(1):229-37. doi: 10.3892/ijo.2013.2151. Epub 2013 Oct 25.


Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.

Dunn EF, Iida M, Myers RA, Campbell DA, Hintz KA, Armstrong EA, Li C, Wheeler DL.

Oncogene. 2011 Feb 3;30(5):561-74. doi: 10.1038/onc.2010.430. Epub 2010 Oct 18.


A let-7 KRAS rs712 polymorphism increases colorectal cancer risk.

Pan XM, Sun RF, Li ZH, Guo XM, Zhang Z, Qin HJ, Xu GH, Gao LB.

Tumour Biol. 2014 Jan;35(1):831-5. doi: 10.1007/s13277-013-1114-3. Epub 2013 Aug 24.


HSP27 expression in primary colorectal cancers is dependent on mutation of KRAS and PI3K/AKT activation status and is independent of TP53.

Ghosh A, Lai C, McDonald S, Suraweera N, Sengupta N, Propper D, Dorudi S, Silver A.

Exp Mol Pathol. 2013 Feb;94(1):103-8. doi: 10.1016/j.yexmp.2012.09.001. Epub 2012 Sep 12.


TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy.

Oden-Gangloff A, Di Fiore F, Bibeau F, Lamy A, Bougeard G, Charbonnier F, Blanchard F, Tougeron D, Ychou M, Boissière F, Le Pessot F, Sabourin JC, Tuech JJ, Michel P, Frebourg T.

Br J Cancer. 2009 Apr 21;100(8):1330-5. doi: 10.1038/sj.bjc.6605008.


Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan.

Graziano F, Canestrari E, Loupakis F, Ruzzo A, Galluccio N, Santini D, Rocchi M, Vincenzi B, Salvatore L, Cremolini C, Spoto C, Catalano V, D'Emidio S, Giordani P, Tonini G, Falcone A, Magnani M.

Pharmacogenomics J. 2010 Oct;10(5):458-64. doi: 10.1038/tpj.2010.9. Epub 2010 Feb 23.


Study of apoptosis-related interactions in colorectal cancer.

Arora H, Qureshi R, Rizvi MA, Shrivastava S, Parihar MS.

Tumour Biol. 2016 Nov;37(11):14415-14425. Epub 2016 Sep 15. Review.


Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.

Kleist B, Kempa M, Novy M, Oberkanins C, Xu L, Li G, Loland C, Poetsch M.

Int J Clin Exp Pathol. 2014 Aug 15;7(9):5927-39. eCollection 2014.


Let-7a microRNA functions as a potential tumor suppressor in human laryngeal cancer.

Long XB, Sun GB, Hu S, Liang GT, Wang N, Zhang XH, Cao PP, Zhen HT, Cui YH, Liu Z.

Oncol Rep. 2009 Nov;22(5):1189-95.


Selective blockade of DCAMKL-1 results in tumor growth arrest by a Let-7a MicroRNA-dependent mechanism.

Sureban SM, May R, Ramalingam S, Subramaniam D, Natarajan G, Anant S, Houchen CW.

Gastroenterology. 2009 Aug;137(2):649-59, 659.e1-2. doi: 10.1053/j.gastro.2009.05.004. Epub 2009 May 13.


Novel small interfering RNA cotargeting strategy as treatment for colorectal cancer.

Valentino JD, Elliott VA, Zaytseva YY, Rychahou PG, Mustain WC, Wang C, Gao T, Evers BM.

Surgery. 2012 Aug;152(2):277-85. doi: 10.1016/j.surg.2012.05.006.

Supplemental Content

Support Center